Harukaze Yamamoto
- Oncology top 5%
- Radiology, Nuclear Medicine and Imaging top 5%
- Pulmonary and Respiratory Medicine
- Immunology
- Molecular Biology
- Co-authors
- Kenji TamuraYasuhiro FujiwaraKan YonemoriChikako ShimizuTakayuki KinoshitaHitoshi TsudaMayu YunokawaMasashi Ando
- Topics
- Cancer Treatment and Pharmacology (6 papers)PARP inhibition in cancer therapy (5 papers)HER2/EGFR in Cancer Research (4 papers)
- Partner nations
- JapanUnited StatesUnited Kingdom
In The Last Decade
Harukaze Yamamoto
24 papers receiving 782 citations
Peers
Comparison fields: 5 of 77
- Oncology 548
- Radiology, Nuclear Medicine and Imaging 285
- Pulmonary and Respiratory Medicine 182
- Immunology 133
- Molecular Biology 127
Countries citing papers authored by Harukaze Yamamoto
This map shows the geographic impact of Harukaze Yamamoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harukaze Yamamoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harukaze Yamamoto more than expected).
Fields of papers citing papers by Harukaze Yamamoto
This network shows the impact of papers produced by Harukaze Yamamoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harukaze Yamamoto. The network helps show where Harukaze Yamamoto may publish in the future.
Co-authorship network of co-authors of Harukaze Yamamoto
This figure shows the co-authorship network connecting the top 25 collaborators of Harukaze Yamamoto. A scholar is included among the top collaborators of Harukaze Yamamoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harukaze Yamamoto. Harukaze Yamamoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 7 | |
| 2 | 25 | |
| 3 | 40 | |
| 4 | 25 | |
| 5 | 24 | |
| 6 | 12 | |
| 7 | 86 | |
| 8 | 228 | |
| 9 | 7 | |
| 10 | 1 | |
| 11 | 2 | |
| 12 | Chemotherapy: Phase Two progress and future perspectives | 1 |
| 13 | 15 | |
| 14 | 245 | |
| 15 | 0 | |
| 16 | 32 | |
| 17 | 12 | |
| 18 | 3 | |
| 19 | 1 | |
| 20 | 22 |
About Harukaze Yamamoto
Harukaze Yamamoto is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Obstetrics and Gynecology, having authored 25 papers that have together received 794 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (6 papers), PARP inhibition in cancer therapy (5 papers) and HER2/EGFR in Cancer Research (4 papers). The work is most often cited by research in Oncology (548 citations), Radiology, Nuclear Medicine and Imaging (285 citations) and Cancer Research (119 citations). Harukaze Yamamoto has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Kenji Tamura, Yasuhiro Fujiwara, Kan Yonemori, Chikako Shimizu, Takayuki Kinoshita, Hitoshi Tsuda, Mayu Yunokawa, Masashi Ando, Noriyuki Katsumata and Makoto Kodaira. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.